心脏性冲击管理:单中心经验与皮肤左心室辅助器件升级策略
Soomal Rafique1, Raj Patel2, Asad Cheema2
1Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
JACC. Case reports
|September 12, 2025
概括
本研究详细介绍了使用升级机械循环支持 (MCS) 设备管理心脏性休克 (CS) 的协议,特别是基于实时血液动力学数据从Impella CP过渡到Impella 5.5,以改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 关键护理医学 关键护理医学
背景情况:
- 心脏性休克 (CS) 在历史上具有很高的死亡率.
- 穿皮左心室辅助装置 (LVAD) 和冲击组方法的进步改善了CS结果.
- 早期的机械循环支持 (MCS) 和血液动力学监测对于管理CS至关重要.
研究的目的:
- 介绍一系列关于使用升级式MCS策略管理CS的案例.
- 根据血液动力学数据,突出显示从Impella CP到Impella 5.5的过渡.
- 为CS管理提出一个可适应的冲击协议.
主要方法:
- 实施一个冲击协议与升级MCS.
- 使用Impella CP和Impella 5.5设备进行临时的左心室支.
- 基于实时血液动力学监测的MCS模式过渡的决策.
主要成果:
- 成功管理CS患者使用MCS逐步升级.
- 通过血液动力学参数指导的MCS设备之间的快速过渡.
- 根据冲击方案管理的患者观察到改善的结果.
结论:
- 一个不断升级的MCS策略,从Impella CP过渡到Impella 5.5,可以有效地管理心脏性休克.
- 实时血液动力学数据对于及时调整MCS设备至关重要.
- 建议的冲击方案在各种临床环境中具有适应性和可复制性.
相关概念视频
Cardiomyopathy V: Interprofessional Care
343
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
343
Cardiomyopathy II: Dilated Cardiomyopathy
480
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
480
Cardiopulmonary Resuscitation IV: Pharmacological Management
679
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
679
Heart Failure VI: Adjunct Therapies
263
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
263
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Cardiomyopathy III: Hypertrophic Cardiomyopathy
416
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
416


